Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Rotavirus vaccine trial in Jamaica.

Christie CD, Duncan ND.

West Indian Med J. 2012 Jul;61(4):405-7.

PMID:
23240476
2.

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.

Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM; Rotavirus Efficacy and Safety Trial (REST) Study Team.

N Engl J Med. 2006 Jan 5;354(1):23-33.

3.

RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.

Vesikari T, Itzler R, Karvonen A, Korhonen T, Van Damme P, Behre U, Bona G, Gothefors L, Heaton PM, Dallas M, Goveia MG.

Vaccine. 2009 Dec 11;28(2):345-51. doi: 10.1016/j.vaccine.2009.10.041. Epub 2009 Oct 29.

PMID:
19879226
4.

The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants.

Clark HF, Offit PA, Plotkin SA, Heaton PM.

Pediatr Infect Dis J. 2006 Jul;25(7):577-83. Review.

PMID:
16804425
5.

Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.

Ciarlet M, Schödel F.

Vaccine. 2009 Dec 30;27 Suppl 6:G72-81. doi: 10.1016/j.vaccine.2009.09.107. Review.

PMID:
20006144
6.

Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants.

Goveia MG, Rodriguez ZM, Dallas MJ, Itzler RF, Boslego JW, Heaton PM, DiNubile MJ; REST Study Team.

Pediatr Infect Dis J. 2007 Dec;26(12):1099-104.

PMID:
18043445
7.

Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.

Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ, Goveia MG, Ward RL, Schödel F, Karvonen A, Drummond JE, DiNubile MJ, Heaton PM.

Vaccine. 2006 May 29;24(22):4821-9. Epub 2006 Mar 31.

PMID:
16621194
8.

Rotavirus live, oral, pentavalent vaccine.

Tom-Revzon C.

Clin Ther. 2007 Dec;29(12):2724-37. doi: 10.1016/j.clinthera.2007.12.018. Review.

PMID:
18201590
9.

The pentavalent rotavirus vaccine, RotaTeq.

Matson DO.

Semin Pediatr Infect Dis. 2006 Oct;17(4):195-9. Review.

PMID:
17055370
10.

Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States.

Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD.

Pediatrics. 2010 Feb;125(2):e208-13. doi: 10.1542/peds.2009-1246. Epub 2010 Jan 25.

PMID:
20100757
11.

RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine.

Chandran A, Santosham M.

Expert Rev Vaccines. 2008 Dec;7(10):1475-80. doi: 10.1586/14760584.7.10.1475. Review.

PMID:
19053204
12.

Characteristics of an ideal rotavirus vaccine.

Reisinger KS, Block SL.

Clin Pediatr (Phila). 2008 Jul;47(6):555-63. doi: 10.1177/0009922808314903. Epub 2008 May 8.

PMID:
18467670
13.

Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants.

Vesikari T, Karvonen A, Puustinen L, Zeng SQ, Szakal ED, Delem A, De Vos B.

Pediatr Infect Dis J. 2004 Oct;23(10):937-43.

PMID:
15602194
15.

Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants.

Salinas B, Pérez Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzábal JP, Cervantes Y, Costa Clemens S, Damaso S, Hardt K, De Vos B.

Pediatr Infect Dis J. 2005 Sep;24(9):807-16.

PMID:
16148848
16.

Rotavirus vaccines--an update.

Dennehy PH.

Vaccine. 2007 Apr 20;25(16):3137-41. Epub 2007 Feb 9. Review.

PMID:
17321017
17.

Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization.

Christie CD, Duncan ND, Thame KA, Onorato MT, Smith HD, Malcolm LG, Itzler RF, Dinubile MJ, Heaton PM.

Pediatrics. 2010 Dec;126(6):e1499-506. doi: 10.1542/peds.2010-1240. Epub 2010 Nov 29.

PMID:
21115586
18.

Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.

Block SL, Vesikari T, Goveia MG, Rivers SB, Adeyi BA, Dallas MJ, Bauder J, Boslego JW, Heaton PM; Pentavalent Rotavirus Vaccine Dose Confirmation Efficacy Study Group.

Pediatrics. 2007 Jan;119(1):11-8.

PMID:
17200266
19.

Update on Rotarix: an oral human rotavirus vaccine.

O'Ryan M, Linhares AC.

Expert Rev Vaccines. 2009 Dec;8(12):1627-41. doi: 10.1586/erv.09.136. Review.

PMID:
19943758
20.

The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine.

Dennehy PH, Goveia MG, Dallas MJ, Heaton PM.

Int J Infect Dis. 2007 Nov;11 Suppl 2:S36-42. doi: 10.1016/S1201-9712(07)60020-4.

Supplemental Content

Support Center